Overview
Signacor Therapeutics, a Belfast-based healthtech startup, has secured €288k (£250k) in funding from VC firm Zinc to develop a new treatment for heart damage and hypertrophic cardiomyopathy (HCM). This investment is part of a €1.1 million (£1 million) seed round expected to close in April 2026. Founded in 2024, Signacor is pioneering 'Cardiaza', a therapy targeting multiple causes of symptomatic HCM, aiming to improve patient quality of life. The funding will support their phase 2a trial plans and regulatory strategy.
Products
Loading...
Recent Deals
Investors: Zinc
Signacor Therapeutics, a Belfast-based healthtech startup, has secured €288k (£250k) in funding from VC firm Zinc to develop a new treatment for heart damage and hypertrophic cardiomyopathy (HCM). This investment is part of a €1.1 million (£1 million) seed round expected to close in April 2026. Founded in 2024, Signacor is pioneering 'Cardiaza', a therapy targeting multiple causes of symptomatic HCM, aiming to improve patient quality of life. The funding will support their phase 2a trial plans and regulatory strategy.